GLP-1 Drug Use Surges 600% as 2% of Americans Take Weight-Loss Medications

An anonymous reader shares a report: More than 2% of Americans are taking the blockbuster class of GLP-1 drugs for overweight or obesity, up nearly 600% over six years, according to a report from FAIR Health given to Axios first. The data from FAIR Health's repository of over 51 billion commercial healthcare claim records shows the explosion in use of the drugs specifically for weight loss -- roughly half of all users.

In all, roughly 4% of Americans were taking GLP-1 drugs in 2024 for either overweight, obesity or Type 2 diabetes (their original approved use). The data shows Novo Nordisk's Ozempic is still by far the most commonly taken GLP-1, followed by Eli Lilly's Mounjaro. The percentage of adults who were prescribed a GLP-1 drug but did not have bariatric surgery increased from 2.5% in 2019 to 11.2% in 2024 while the the percentage of adult patients who had bariatric surgery decreased 41.8%.

Read more of this story at Slashdot.